US President Donald Trump on Friday, July 24, signed a number of orders aimed at reducing the cost of vital prescription drugs in the country. This is stated in a statement from the White house.
In particular, the availability of insulin and epinephrine increases, and the re-import of insulin products produced in the United States is allowed.
One of the orders is intended to put an end to transactions through which intermediaries would benefit from the benefits and discounts provided for consumers and patients.
Trump also decreed that the United States pay the lowest purchase price for medicines on the international market.
On May 12, the American leader announced the launch of a campaign aimed at reducing drug prices in the country.
According to the Hill, the sudden adoption of the documents may be due to the upcoming presidential election and pressure on the head of state on the issue of health care, especially after his support for the repeal of the affordable care act.